Research - South San Francisco, California, United States
At Ab Initio, we are identifying therapeutic antibodies that activate and inactivate G-protein coupled receptors. This category of receptor includes a rich landscape of clinically important targets, but the identification of biologic drugs that can specifically modulate their activity has proved historically difficult. Ab Initio's proprietary technologies and specialized expertise provide a unique advantage in meeting this urgent need. Our current programs include targets important for cardiovascular disease, metabolic disorders, ophthalmology, and cancer.